Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL VALERATE ESTRADIOL VALERATE DIENOGEST versus LYGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL VALERATE ESTRADIOL VALERATE DIENOGEST versus LYGEN.
ESTRADIOL VALERATE; ESTRADIOL VALERATE; DIENOGEST vs LYGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol valerate is a prodrug of estradiol, an estrogen receptor agonist. Dienogest is a progestin with partial antiandrogenic activity, acting as a progesterone receptor agonist with antiovulatory and endometrial antiproliferative effects.
Lysergic acid diethylamide (LSD) acts as a partial agonist at serotonin 5-HT2A receptors in the brain, leading to altered glutamatergic signaling and neural network modulation.
One tablet daily containing estradiol valerate 2 mg and dienogest 3 mg (oral).
For adults, administer 500 mg orally twice daily with or without food.
None Documented
None Documented
Estradiol valerate: Terminal half-life is approximately 13-14 hours for estradiol. Dienogest: Terminal half-life is about 10-11 hours. The combination allows for once-daily dosing with sustained hormone levels.
12 hours; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min)
Estradiol valerate and dienogest: Urinary excretion accounts for approximately 50-60% of total clearance, primarily as glucuronide conjugates of estradiol and dienogest metabolites. Fecal/biliary excretion accounts for 30-40% of dienogest and its metabolites. For estradiol valerate, about 30% of metabolites are excreted in bile and feces.
Renal (90% as unchanged drug), biliary/fecal (10%)
Category D/X
Category C
Estrogen
Estrogen